3 nominees · 5 ballot items.
Elect three Class II directors; ratify KPMG LLP as independent auditor; advisory approval of named executive officer compensation; approve amendment to Certificate of Incorporation to give the Board power to adopt, amend or repeal Bylaws; ratify prior Board-adopted amendments to the Bylaws (three items).
Elect three Class II directors nominated by the Board to serve until the 2027 Annual Meeting.
Ratify KPMG LLP as the Company’s independent registered public accounting firm for fiscal year 2026.
Non-binding advisory vote to approve the compensation of the named executive officers as disclosed in the Proxy Statement.
Approve an amendment to the Certificate of Incorporation to provide the Board the power to adopt, amend or repeal the Company's Bylaws.
The proposal asks stockholders to approve an amendment to the Company’s Amended and Restated Certificate of Incorporation to grant the Board explicit authority to adopt, amend or repeal the Company’s Bylaws. Management seeks this approval because the current Certificate of Incorporation does not include an express board-authority clause, even though the Board and the registration statement at IPO reflected an intent to give the Board that power. The change is presented as consistent with Delaware practice and with the governance documents originally disclosed at IPO, and management argues it is a standard provision that most public companies and peer companies have. The board recommends approval because board authority to amend bylaws reduces delay and expense associated with routine governance and ministerial changes and allows the company to respond quickly to evolving circumstances, while leaving stockholder authority to adopt, amend or repeal bylaws intact. The proposal will require a majority vote of outstanding shares to approve and management emphasizes that the amendment is not intended to limit stockholder rights. Investors should weigh the governance trade-off: it grants the board more unilateral speed and flexibility, which can be beneficial for efficient governance but may reduce the frequency with which stockholders vote on bylaws changes. Given the company’s rationale, peer practice, and the board’s existing independent composition, management suggests the change aligns with common governance norms. The board’s recommendation cites operational efficiency and alignment with the company’s IPO-era disclosures as primary rationales.
Ratify three groups of bylaws amendments previously adopted by the Board (Feb 21, 2018; Dec 2, 2022; May 22, 2025) concerning advance notice provisions, procedural mechanics for stockholder nominations and elimination of a sole supermajority voting requirement.
This proposal asks stockholders to ratify, under Delaware General Corporation Law Section 204, three sets of bylaw amendments the Board previously adopted: (a) 2018 amendments tightening advance notice requirements and removing references to Roark Capital; (b) 2022 amendments adding procedural mechanics and disclosure requirements for stockholder nominations and aligning bylaws with DGCL; and (c) 2025 amendment eliminating the sole supermajority voting requirement. Management adopted these bylaws previously but now seeks retroactive ratification because the Certificate of Incorporation lacked an express board power to amend bylaws, potentially rendering those prior amendments defective. Ratification would validate them retroactively to their original adoption dates. The Board argues ratification is in shareholders’ interests to remove legal uncertainty over governance rules and to preserve the operational benefits of those amendments. Investors should consider that ratification limits the window for bringing certain legal challenges under Delaware law (120 days after approval) and that ratification effectively endorses the content of the previously adopted changes—some of which tighten stockholder nomination and disclosure obligations. The board recommends a vote FOR to cure any legal defect and to confirm governance updates that the Board believes improve clarity and alignment with Delaware law.
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | PRICE T ROWE ASSOCIATES INC /MD/ | 6.53% | 1,778,643 | $276M |
| 2 | BlackRock, Inc. | 6.27% | 1,706,163 | $264M |
| 3 | FMR LLC | 5.52% | 1,504,562 | $233M |
| 4 | T. Rowe Price Investment Management, Inc. | 4.71% | 1,282,651 | $199M |
| 5 | Darsana Capital Partners LP | 4.59% | 1,250,000 | $194M |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 4.54% | 1,235,579 | $191M |
| 7 | VANGUARD PORTFOLIO MANAGEMENT LLC | 4.24% | 1,155,248 | $179M |
| 8 | AMERICAN CENTURY COMPANIES INC | 4.08% | 1,110,036 | $172M |
| 9 | MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 3.64% | 992,532 | $154M |
| 10 | STATE STREET CORP | 3.11% | 847,044 | $131M |
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.